Our Region

Join Distribution List!

News and Activities

Finally—A new four-month treatment for drug-susceptible TB!

October 21, 2020 –Treatment Action Group (TAG) and the Community Research Advisors Group (CRAG) welcome the news of a safe and effective regimen for shortening tuberculosis (TB) treatment to just four months. Reported at the 51st Union World Conference on Lung Health, a landmark publicly-funded phase III clinical trial, conducted at 34 sites in 13 countries, found that this regimen containing rifapentine and moxifloxacin performed as well as the six-month standard regimen.

The TBTC Study 31/ACTG A5349 trial was a collaboration between the (CDC) TB Trials Consortium (TBTC) and (NIH) AIDS Clinical Trials Group (ACTG). This phase III clinical trial enrolled over 2,500 people with TB, making it the largest TB treatment trial in decades.




The Spectrum of Tuberculosis from Infection to Disease - TB at a Glance: Third Edition

Now available for download! See video below for more information!


Download your copy at: https://heartlandntbc.org/products/


Stop TB Partnership shows that under a three-month lockdown and a protracted 10-month restoration of services, the world could see an additional 6.3 million cases of TB between 2020 and 2025 and an additional 1.4 million TB deaths during that same period.


New Consultation Request Method

The Heartland National TB Center Medical Consultation team is adding a new method to take consultation requests. The nursing team will receive your consultation request via our consultation email at heartlandconsultation@uthct.edu. Please help us in testing this new method.